Minireviews
Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 28, 2018; 24(24): 2582-2595
Published online Jun 28, 2018. doi: 10.3748/wjg.v24.i24.2582
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
Maria Guarino, Anna Sessa, Valentina Cossiga, Federica Morando, Nicola Caporaso, Filomena Morisco, On behalf of the Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver
Maria Guarino, Anna Sessa, Valentina Cossiga, Federica Morando, Nicola Caporaso, Filomena Morisco, Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples 80131, Italy
Author contributions: All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version.
Conflict-of-interest statement: None of the authors had personal or financial conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Nicola Caporaso, MD, Full Professor, Gastroenterology Unit, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Via S. Pansini5, Naples 80131, Italy. nicola.caporaso@unina.it
Telephone: +39-08-17462761 Fax: +39-08-17464746
Received: April 19, 2018
Peer-review started: April 21, 2018
First decision: May 9, 2018
Revised: May 18, 2018
Accepted: June 9, 2018
Article in press: June 12, 2018
Published online: June 28, 2018
Core Tip

Core tip: A significant debate about the impact of direct-acting antiviral agents (DAAs) on the development of hepatocellular carcinoma (HCC) is currently ongoing. After a full review of the published literature, the evidence does not suggest that there is a higher rate of de novo HCC occurrence or recurrence after DAA therapy in patients with previous hepatitis C virus infection.